Literature DB >> 18463840

[Supportive care for malignant melanoma].

P Mohr1.   

Abstract

In the systemic therapy of malignant melanoma, many forms of chemotherapy, immunotherapy, polychemotherapy and immunopolychemotherapy are being use. When administering such forms of therapy, optimal supportive care is essential. Important aspects include control of nausea and vomiting, prophylaxis and treatment of bone marrow failure, reducing fatigue and being alert to cutaneous side effects. Specific recommendations for all of these dermato-oncologic problems are provided in detail.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18463840     DOI： 10.1007/s00105-008-1564-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  12 in total

1.  Hodgkin's disease survivors more fatigued than the general population.

Authors:  J H Loge; A F Abrahamsen; O Ekeberg; S Kaasa
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 2.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Authors:  M S Aapro; D A Cameron; R Pettengell; J Bohlius; J Crawford; M Ellis; N Kearney; G H Lyman; V C Tjan-Heijnen; J Walewski; D C Weber; C Zielinski
Journal:  Eur J Cancer       Date:  2006-06-05       Impact factor: 9.162

3.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

4.  Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.

Authors:  P J Hesketh
Journal:  Oncologist       Date:  1999

5.  Fatigue, depression and quality of life in cancer patients: how are they related?

Authors:  M R Visser; E M Smets
Journal:  Support Care Cancer       Date:  1998-03       Impact factor: 3.603

6.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

7.  Does methylphenidate reduce the symptoms of chronic fatigue syndrome?

Authors:  Daniel Blockmans; Philippe Persoons; Boudewijn Van Houdenhove; Herman Bobbaers
Journal:  Am J Med       Date:  2006-02       Impact factor: 4.965

8.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

Authors:  F Roila; P J Hesketh; J Herrstedt
Journal:  Ann Oncol       Date:  2005-11-28       Impact factor: 32.976

9.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

Authors:  J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

10.  Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.

Authors:  Steven M Grunberg; Robert R Deuson; Panagiotis Mavros; Olga Geling; Mogens Hansen; Giorgio Cruciani; Bruno Daniele; Gerard De Pouvourville; Edward B Rubenstein; Gedske Daugaard
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.